Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2018 07:01 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis

–100% (three out of three) of patients have now met the primary endpoint in achieving ≥ 50% clinical response with MAT2203 – – Study has met predetermined statistical endpoint for success – – All...
December 14, 2017 07:01 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors

BEDMINSTER, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for...
November 15, 2017 07:35 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update

BEDMINSTER, N.J., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for...
October 11, 2017 08:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

BEDMINSTER, N.J., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for...
September 19, 2017 09:20 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference

BEDMINSTER, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for...
September 12, 2017 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001

– MAT9001 is a uniquely engineered omega-3 fatty acid comprising docosapentaenoic acid (DPA) for the treatment of hypertriglyceridemia – – MAT9001 demonstrated superiority versus Amarin’s Vascepa® on...
August 08, 2017 06:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501

Second quarter marked by significant clinical progress with compelling overall Phase 2 data from two studies of flagship product candidate MAT2203Company plans to engage FDA to review overall data...
August 03, 2017 08:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference

- Presentation with live audio webcast on Thursday, August 10th at 11:00 AM EDT - BEDMINSTER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a...
August 01, 2017 08:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Host Quarterly Update Conference Call

– Conference call with live audio webcast on Tuesday, August 8th at 8:30 am ET – – Management to outline and confirm clinical and regulatory strategy of flagship product candidate MAT2203 toward...
June 26, 2017 06:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis

BEDMINSTER, N.J., June 26, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for...